A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase III Clinical Trial for the Efficacy and Safety of Fugliglitinate Benzoate Tablets in Patients With Type 2 Diabetes Who Cannot be Effectively Controlled by Metformin

Shenzhen Salubris Pharmaceuticals Co., Ltd.1 site in 1 country408 target enrollmentMay 6, 2020

ConditionsDiabetes Mellitus, Type 2

InterventionsSAL067 Placebo

DrugsSAL067 Placebo

Overview

Phase: Phase 3
Intervention: SAL067
Conditions: Diabetes Mellitus, Type 2
Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
Enrollment: 408
Locations: 1
Primary Endpoint: HbA1c change from baseline at week 24
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is the phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and long-term safety of SAL067 in T2DM patients uncontrolled by metformin, comprising 24 weeks of double-blind treatment period followed by an open-label treatment period, making up a total of 52 weeks.

Detailed Description

All eligible subjects would enter the 24 weeks of double-blind treatment period and were randomized into the SAL067 group (12 mg once daily) or placebo group at a 2:1:1 ratio. After 24 weeks of double-blind treatment, subjects would enter the extended open-label treatment period. Subjects in the placebo group were to be switched to SAL067 (12 mg once daily) treatment, while patients in the SAL067 groups continued the same treatment until the end of the whole 52 weeks.

Registry

clinicaltrials.gov

Start Date

May 6, 2020

End Date

May 24, 2022

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Type 2 diabetes patients who meet the diagnostic criteria for diabetes issued by the World Health Organization (WHO) in 1999;
•Men or women aged 18 to 75 years old at the day of signing the informed consent;
•Body mass index: BMI 19kg/m2 to 35kg/m2, \[BMI=weight (kg)/height 2 (m2)\];
•Subjects treated with metformin≥ 1500mg/day constantly for at least 8 consecutive weeks before screnning;
•Glycated hemoglobin (HbA1c): Screening period: HbA1c 7.5% to 10.5% (tested by the research center), when randomly enrolled: HbA1c 7.0% to 10.0% (central laboratory test) Measurement);
•Screening period and random time fasting blood glucose \<=13.9mmol/L.

Exclusion Criteria

•Drug compliance during the introduction period \<80% or \>120%;
•Use other hypoglycemic drugs other than test drugs during the introduction period;
•The patient may have any contraindications, allergies or hypersensitivity to fuglitagliptin (including study drug and placebo) or its excipients, DPP4 drugs, metformin;
•Before screening, have any of the following endocrine-related medical history or evidence:
•Diabetes other than type 2 diabetes, such as type 1 diabetes, single-gene mutation diabetes, diabetes caused by pancreatic injury or secondary diabetes, such as diabetes caused by Cushing's syndrome or acromegaly;
•diabetic ketoacidosis, hyperglycemia and hyperosmolarity, lacticacidosis and other acute complications of diabetes within 6 months before screening;
•severe hypoglycemia episodes (such as sleepiness caused by hypoglycemia, unconsciousness, nonsense, and even coma), or a serious history of unconscious hypoglycemia;
•Before screening, there is a history or evidence of any of the following diseases:
•Unstable angina, stroke or transient ischemic attack, myocardial infarction, coronary artery bypass graft or percutaneous coronary intervention (diagnostic angiography is allowed of);
•Decompensated heart failure before screening (New York Heart Association NYHA heart function grades III and IV, persistent and clinically significant arrhythmia;

Arms & Interventions

SAL067

SAL067 12mg once daily

Intervention: SAL067

Placebo

placebo once daily

Intervention: Placebo

Outcomes

Primary Outcomes

HbA1c change from baseline at week 24

Time Frame: Baseline and week 24

Change From Baseline in Hemoglobin A1c (HbA1c) at week 24

Secondary Outcomes

HbA1c change from baseline at week 4,week 12,week 40 and week 52(Baseline, week 4, week 12, week 40 and week 52)
FPG change from baseline at week 4, week 8, week 12, week 16, week 24, week 40 and week 52(Baseline, week 4, week 8, week 12, week 24, week 40 and week 52)
Fasting c-peptide change from baseline at week 24 and week 52(Baseline, week 24 and week 52)
Insulin sensitivity change (calculated by HOMA-IS) from baseline at week 24 and week 52(Baseline, week 24 and week 52)
Percentage of patients with HbA1c <7.0% and HbA1c <6.5% at week 24 and week 52(Baseline, week 24 and week 52)
Percentage of patients required use of rescue therapy at week 24 and week 52(Baseline, week 24 and week 52)
eatic β-cell function change (calculated by HOMA-β ) from baseline at week 24 and week 52(Baseline, week 24 and week 52)